Scienture Holdings, Inc. (NASDAQ:SCNX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The US$5.3m market-cap company posted a loss in its most recent financial year of US$42m and a latest trailing-twelve-month loss of US$38m shrinking the gap between loss and breakeven. Many investors are wondering about the rate at which Scienture Holdings will turn a profit, with the big question being “when will the company breakeven?” In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Scienture Holdings is bordering on breakeven, according to some American Healthcare Services analysts. They expect the company to post a final loss in 2027, before turning a profit of US$9.6m in 2028. So, the company is predicted to breakeven approximately 2 years from today. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 72% is expected, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.

Underlying developments driving Scienture Holdings' growth isn’t the focus of this broad overview, but, take into account that by and large a healthcare tech company has lumpy cash flows which are contingent on the product and stage of development the company is in. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

Check out our latest analysis for Scienture Holdings

Before we wrap up, there’s one aspect worth mentioning. The company has managed its capital judiciously, with debt making up 17% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

Next Steps:

There are too many aspects of Scienture Holdings to cover in one brief article, but the key fundamentals for the company can all be found in one place – Scienture Holdings' company page on Simply Wall St. We've also put together a list of key aspects you should further examine:

1. Historical Track Record: What has Scienture Holdings' performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Scienture Holdings' board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.